BTCC / BTCC Square / Global Cryptocurrency /
Needham Downgrades Hims & Hers Stock Amid Novo Nordisk Partnership Fallout

Needham Downgrades Hims & Hers Stock Amid Novo Nordisk Partnership Fallout

Global Cryptocurrency
Release Time:
2025-06-24 06:47:02
0
BTCCSquare news:

Hims & Hers Health (HIMS) shares plummeted 35% Monday after Novo Nordisk terminated their partnership, alleging illegal sales of Wegovy copycats. Needham analyst Ryan MacDonald downgraded HIMS to Hold, citing litigation risks and competitive disadvantages in the GLP-1 drug market.

Wall Street now views HIMS as exposed to regulatory scrutiny under FDA's 503A compounded drug provisions. The stock's removal from Needham's Conviction List reflects eroded confidence in its growth trajectory amid legal uncertainties.

Articles on this site are sourced from public networks or curated by AI for informational purposes only and do not represent BTCC’s views. Original rights belong to the respective authors. For copyright concerns, please contact [email protected]. BTCC assumes no liability for the accuracy, timeliness, or completeness of this information, and disclaims all liability arising from reliance on such content. This content is for reference only and should not be taken as investment, legal, or commercial advice.

|Square

Get the BTCC app to start your crypto journey

Get started today Scan to join our 100M+ users